Liu Dong, Xia A-Dong, Xing Yue-Long, Zhang Kai, Chen Dan
Department of Hepatobiliary and Pancreatic Gastroenterology, Affiliated Jinhua Hospital of Wenzhou Medical University, Jinhua People's Hospital, Jinhua, Zhejiang Province, China.
Gastroenterol Res Pract. 2024 May 14;2024:4850745. doi: 10.1155/2024/4850745. eCollection 2024.
To explore the correlations of cancer-related fatigue (CRF) with clinicopathological features and quality of life in gastric cancer.
Using a convenient sampling method, 230 patients with gastric cancer admitted to our hospital from March 2020 to July 2022 were collected. They were divided into the fatigue group ( = 152) and the nonfatigue group ( = 78) according to the presence/absence of CRF. Relevant data were collected and compared.
Statistically significant differences were found between the two groups in age ratio ( = 41.671, < 0.001), T stage ratio ( = 9.973, = 0.019), N stage ratio ( < 0.001), PS score ( < 0.001), and the degree of gastric cancer thickening (14.21 ± 3.32 vs. 12.12 ± 3.81 mm, = 4.572, < 0.001). Patients with gastric cancer had the lowest CRF Brief Fatigue Inventory (BFI) score for general activities (2.26 ± 0.37) and high scores for work activities (6.23 ± 0.24) and enjoyment of life (7.11 ± 1.34). Pearson's correlation analysis revealed a positive correlation between patient emotions and the CRF BFI score ( = 0.443, = 0.001). Patients with mild, moderate, and severe CRF showed statistically significant differences in physical functioning (83.34 ± 21.12 vs. 65.23 ± 21.14 vs. 32.25 ± 17.29, = 15.382, < 0.001), role emotional (72.53 ± 21.21 vs. 67.33 ± 27.56 vs. 54.37 ± 26.45, = 14.483, < 0.001), fatigue (49.12 ± 18.44 vs. 54.61 ± 26.64 vs. 67.51 ± 14.27, = 13.581, < 0.001), bodily pain (56.56 ± 25.12 vs. 76.43 ± 21.71 vs. 80.32 ± 12.39, = 14.582, < 0.001), appetite reduction (57.45 ± 25.47 vs. 69.51 ± 16.21 vs. 76.23 ± 27.58, = 14.592, < 0.001), and overall health status and quality of life (67.21 ± 19.45 vs. 53.43 ± 22.32 vs. 43.43 ± 12.52, = 16.494, < 0.001). After chemotherapy, the average CRF BFI scores of the partial remission (PR), disease stability (SD), and disease progression (PD) groups all reduced than those before chemotherapy (all < 0.05). At 3 months of follow-up, a comparison of the average CRF BFI scores with those before chemotherapy revealed a decrease in the SD and PR groups and an increase in the PD group.
In conclusion, CRF is correlated with age, T stage, and N stage in gastric cancer. The later the T and N stages, the more significant the effect on fatigue. Moreover, CRF can also affect the quality of life in gastric cancer, and the severer the CRF, the poorer the quality of life.
探讨胃癌患者癌因性疲乏(CRF)与临床病理特征及生活质量的相关性。
采用方便抽样法,收集2020年3月至2022年7月我院收治的230例胃癌患者。根据是否存在CRF将其分为疲乏组(n = 152)和非疲乏组(n = 78)。收集相关数据并进行比较。
两组在年龄比例(χ² = 41.671,P < 0.001)、T分期比例(χ² = 9.973,P = 0.019)、N分期比例(P < 0.001)、PS评分(P < 0.001)以及胃癌增厚程度方面(14.21 ± 3.32 vs. 12.12 ± 3.81 mm,t = 4.572,P < 0.001)存在统计学显著差异。胃癌患者在一般活动方面的CRF简明疲乏量表(BFI)得分最低(2.26 ± 0.37),在工作活动方面得分较高(6.23 ± 0.24),在生活乐趣方面得分较高(7.11 ± 1.34)。Pearson相关性分析显示患者情绪与CRF BFI得分呈正相关(r = 0.443,P = 0.001)。轻度、中度和重度CRF患者在身体功能(83.34 ± 21.12 vs. 65.23 ± 21.14 vs. 32.25 ± 17.29,F = 15.382,P < 0.001)、角色情绪(72.53 ± 21.21 vs. 67.33 ± 27.56 vs. 54.37 ± 26.45,F = 14.483,P < 0.001)、疲乏(49.12 ± 18.44 vs. 54.61 ± 26.64 vs. 67.51 ± 14.27,F = 13.581,P < 0.001)、身体疼痛(56.56 ± 25.12 vs. 76.43 ± 21.71 vs. 80.32 ± 12.39,F = 14.582,P < 0.001)、食欲减退(57.45 ± 25.47 vs. 69.51 ± 16.21 vs. 76.23 ± 27.58,F = 14.592,P < 0.001)以及总体健康状况和生活质量方面(67.21 ± 19.45 vs. 53.43 ± 22.32 vs. 43.43 ± 12.52,F = 16.494,P < 0.001)存在统计学显著差异。化疗后,部分缓解(PR)、病情稳定(SD)和疾病进展(PD)组的平均CRF BFI得分均低于化疗前(均P < 0.05)。在随访3个月时,将平均CRF BFI得分与化疗前进行比较,发现SD组和PR组得分降低,PD组得分升高。
总之,CRF与胃癌的年龄、T分期和N分期相关。T和N分期越晚,对疲乏的影响越显著。此外,CRF还会影响胃癌患者的生活质量,CRF越严重,生活质量越差。